WALTHAM, Mass., Dec. 3 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that the China Doping Control Center (CDCC) has selected the company as one of its major suppliers of instrumentation and software for the testing of athletes at the 29th Olympic Games in Beijing. The CDCC has been accredited by the Chinese government and the International Olympic Committee (IOC) to conduct all doping control analyses during the 2008 Summer Olympics.
The company will provide the CDCC with a range of high precision and high performance Thermo Scientific brand mass spectrometry (MS) instruments, including DFS Sector Field GC/MS systems, the DELTA V isotope ratio mass spectrometer and triple-quadrupole TSQ Quantum(TM) Access LC/MS systems. These instruments and associated software will enable the CDCC to respond to the high volume of samples expected at the Summer Olympics. Thermo Fisher has also agreed to provide technical and application assistance to the CDCC to ensure uninterrupted operation and secure handing of athlete samples throughout the event.
"Identifying illegal performance-enhancing substances that are used in sports competition is a growing global challenge -- one made even more difficult by the development of sophisticated drugs that are increasingly difficult to detect," said Marijn E. Dekkers, president and chief executive officer of Thermo Fisher Scientific. "Our analytical instrumentation is ideally suited to meet this challenge, providing the high specificity and sensitivity, high throughput and reliability required in today's sports environment."
The CDCC testing program will start before the opening of the competition, and continue from the athlete check-in at the Olympic Village until the end of the games. All samples will be analyzed strictly in accordance with the IOC anti-doping rules for banned substances.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With an annual revenue rate of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit http://www.thermofisher.com.
The following constitutes a "Safe Harbor" statement under the Private
Securities Litigation Reform Act of 1995: This press release contains
forward- looking statements that involve a number of risks and
uncertainties. Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements are set
forth in the company's Quarterly Report on Form 10-Q for the quarter ended
September 29, 2007, under the caption "Risk Factors," which is on file with
the Securities and Exchange Commission and available in the "Investors"
section of our Website under the heading "SEC Filings." We also may make
forward-looking statements about the benefits of the merger of Thermo
Electron and Fisher Scientific, including statements about future financial
and operating results, the new company's plans, objectives, expectations
and intentions and other statements that are not historical facts.
Important factors that could cause actual results to differ materially from
those indicated by forward-looking statements include risks and
uncertainties relating to: the risk that the businesses will not be
integrated successfully; the risk that the cost savings and any other
synergies from the transaction may not be fully realized or may take longer
to realize than expected; disruption from the transaction making it more
difficult to maintain relationships with customers, employees or suppliers;
competition and its effect on pricing, spending, third-party relationships
and revenues; the need to develop new products and adapt to significant
technological change; implementation of strategies for improving internal
growth; use and protection of intellectual property; dependence on
customers' capital spending policies and government funding policies;
realization of potential future savings from new productivity initiatives;
general worldwide economic conditions and related uncertainties; the effect
of changes in governmental regulations; the effect of exchange rate
fluctuations on international operations; the effect of laws and
regulations governing government contracts; the effect of competing with
certain of our customers and suppliers; and the effect of rapid changes in
the healthcare industry. While we may elect to update forward-looking
statements at some point in the future, we specifically disclaim any
obligation to do so, even if our estimates change and, therefore, you
should not rely on these forward-looking statements as representing our
views as of any date subsequent to today.
Media Contact Information:
Investor Contact Information:
|SOURCE Thermo Fisher Scientific Inc.|
Copyright©2007 PR Newswire.
All rights reserved